Presurgical endocrine therapy less toxic than chemotherapy for ER-positive breast cancer
(Massachusetts General Hospital) Neoadjuvant endocrine therapy -- designed to reduce the size of breast tumors before surgical removal -- appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast cancer with considerably fewer side effects.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Endocrine Therapy | Hospitals | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Toxicology